Bildkälla: Stockfoto

Moberg Pharma: A setback for the US study - Redeye

Redeye comments on the lowered expectations of the primary endpoint in the ongoing phase 3 trial.

Redeye comments on the lowered expectations of the primary endpoint in the ongoing phase 3 trial.
Börsvärldens nyhetsbrev
ANNONSER